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Abstract. Ivermectin treatment has evaluated for its efficacy and side reactions in sixty patients of
Orissa with Bancroftian filarial infection and microfilaremia. Ivermectin was administered as a single oral
dose at four dosage levels (20, 50. 100 and 200 µg/kg), and both microfilarial clearance and associated
side reactions were monitored in a double blind fashion. Blood microfilariae were cleared in all patients at
all dosages within 1 to 4 days. In most patients microfilariae reappeared by thi d month. The microfilaria
appearance by third and sixth month averaged 12.2 to 44 percent of pretreatment values in the fourstudy
groups. Side reactions were encountered in almost all patients, the commonest being fever. headache,
weakness, myalgia and cough which occured most prominently 12 to 72 hours after treatment. Side reac-   
tions were more frequent and severe in patients with high microfilaria counts. Clinical reaction scores for
each group were independent of the dose administered. The 200 µg dose group showed significantly
more rapid microfilariae clearance and its delayed reappearance as compared with the other dosage
groups and without inducing significantly greater clinical reaction scores.
INTRODUCTION
Lymphatic filariasis is a major health problem
in India, with 22 million people being microfilare-
mic and another 16 million showing symptoms
and signs of filariasis (Sharma et al, 1983; WHO,
1984). Orissa, situated on the eastern coast of the
country is highly endemic for Bancroftian filariasis,
where the prevalence rate of the disease and
microfilaremia is as high as 37.2% and 15.8% in
certain endemic villages (Kar, 1986). With diethyl-
carbamazine (DEC) as the only drug available for
treatment of human filariasis, the goal of the
National Filariasis Control Program (NFCP)
could not be achieved as multiple doses of the
drug over 2 weeks had to be given and because of
the associated side effects (Sasa et al. 1963: Sunda-
ram et al. 1971; Hawking, 1979). Hence, it appeared
essential to have an alternative drug that was safe,
elective, easy to administer and more acceptable
to population requiring treatment.
maximal microfilaricidal effect have recently been
carried out in a number of places (Diallo et al.
1987; Kumaraswami et al. 1988; Roux et al, 1989).
While a single oral dose has been found to be just
as effective in decreasing microfilaremia as the
usual full course of DEC for 3 months post treat-
ment (Ottensen t al, 1990), there has been some
variation in the estimation of the optimal drug
dose in different regions. This difference might
possibly result from the variations which exist in
the population characteristics studied or from dif-
ferences in the parasites in various endemic areas.
In Orissa. where the density of infection is generally
high and certain atypical manifestations of infection
have been described (Kar, 1986) a trial on iver-
mectin was initiated to determine the optimal
dosage of the drug needed for clearance of W.
bancrofti microfilaremia with fewest associated
side reactions.
Ivermectin is now the drug of choice in oncho-
cerciasis and more than 1,000,000 people have
already been successfully treated in Africa and
Latin America (Lariviere t al. 1985). It has been
shown to be as effective as DEC. Studies on the
susceptibility of Wuchereria bancrofti infection to
ivermectin and the optimal dosage required for
MATERIALS AND METHODS
Patient population
Asymptomatic microfilaria carriers from ende-
mic villages were detected through blood surveys.
Sixty men aged 18-40 years (median age 22.5
yea s) with W. bancrofti infection (more than 100
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mf/ml) were included in the trial. All of them wereThe microfilaria levels of the blood were assessed
above 31 kg body weight. Each patient consentedat 12 and 36 hours and on days 7, 14, 30, 90 and
to participate in the trial after the nature and180 after treatment. The results were expressed as
scope of the study had been explained. The treat-the number of microfilariae per milliliter of blood
ment protocol was approved by the ethical com-or a percentage of mean number of the pretreat-
mittee of the Indian Council of Medical Research.ment count for each patient.
Pre-drug assessment Assessment of side effects
Clinical: All individuals were hospitalized for IO
days (3 days before receiving the drug and for at
least a week thereafter). Each patient was subjected
to a pretreatment evaluation which included detailed
clinical history, physical examination, hematolo-
gic evaluation (hematocrit, hemoglobin percentage,
total and differential white cell counts), serum
chemistry studies (bilirubin, aspartate amino-
transferase, alanine aminotransferase, alkaline
phosphatase and creatinine), urinalysis (routine
and microscopic), chest X-ray and electrocardio-
gram.
Each adverse reaction (like fever, anorexia.
cough, chill, weakness, headache, etc) was given a
scale of 0-3 (none, mild, moderate or severe). The
sid  reaction scores of all 7 days in the hospital
were summed to generate the ‘total reaction scores’
 for each individual. These scores were used to
assess the relationship between side effects of
treatment and either the drug dose or parasite
loads of patients.
Statistical analysis
Parasitological: Blood microfilaria (mf) levels per
ml of blood were assessed at 9.30 pm thrice before
treatment by Nuclepore membrane filtration
(using 3 µm filter from Nuclepore Corporation.
Pleasanton, CA, USA). The average value of the
mf count of the three pre-drug days was taken as
pre-drug mf count.
Study design                          
After the pre-treatment evaluation, the subjects
were randomly allocated to four different dosages
of ivermectin (20, 50, 100 and 200 µg/kg). The
drug was administered as single oral dose to each
patient on an empty stomach at 9.00 am in the
morning. The drug allocation and the assessment
were carried out in a double blind fashion.
Analysis of variance was carried out to observe
the effect of different drug dosage with the micro-
filaria level at different points of time. Statistical
evaluations were also done by student’s r-test,
wherever necessary. For comparison involving
microfilaremia levels, microfilaria counts were
logarithmically transformed before the analysis
were carried out.
RESULTS
Efficacy of ivermectin in clearing microfilaremia
Post-drug assessment       
The vital signs and clinical findings were moni-
tored by a check list every four hours for two
days, every 6 hours for next two days and daily
thereafter for the remaining three days. Serum
chemistry studies were carried out in the 2nd and
7th days of drug administration. Post treatment
periodic follow up examinations were carried out
in the hospital on day 14, 30, 90 and 180. These
included clinical history, physical examination
and complete blood cell count.
The pretreatment microfilaria count of sixty
study cases ranged from 123 to 10,000 mf/ml of
blood (Median-1, 698, GM = 1.338). The geometric
means (GM) of microfilaria of the four groups of
patients receiving 20, 50, 100 and 300 µg/kg of
the drug were 1,283.7, 1,537.2, 812.81 and 2,000.1/ml
of blood respectively. These counts were signifi-
cantly different (p < 0.001) from each other. There
was an abrupt fall (p<0.01) in the mean (GM)
bl od microfilaria levels after the single dose of
ivermectin, with nearly 98% of the circulating
microfilariae being cleared within 12 hours in all
dose groups. In most patients, the mf count dropped
to 0-2/ml of blood within 14 days of drug adminis-
tra ion except in one case whose lowest count
achieved 67/ml (drug dose 20 µg/kg, pre-
treatment mf count; 721/ml). The microfilaria
clearance was most effective in the group receiving
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200 µg/kg dosage. However these mf clearances
were not permanent. The count started to rise
gradually. The average (GM) mf levels rose to
12.2 and 44% of the pre-treatment value at the
third and sixth months, respectively. In addition
to the initial clearance being significantly less
rapid in the group that received the 20 µg dose,
the return of microfilaremia came more rapidly.
The highest dose group (200 µg/kg) which had
experienced the most abrupt initial fall of parasite
count, had a reappearance rate that was also rela-
tively slow. The mf reappearance rate at sixth
month was 21 and 66 % of pre-drug counts in the
200 and 20 µg dose groups, respectively (Fig 1).
In the 50 and 100 µg groups the mf clearance
and reappearance followed intermediate patterns.
Analysis of variance revealed significant effect
(F= 64.36, p<0.005) of different dosage on the
clearance of microfilaria level.
Side effects
The severity of each clinical finding was graded
on a scale of 0 to 3 (none, mild, moderate or severe).
Within 12-24 hours of drug administration 97% of
the patients experienced mild to moderate side
reactions. The commonest side effects were fever,
headache, weakness and lethargy. The time course
of these events was similar for all patients. These
reaction peaked in intensity between 24-48 hours
of therapy and subsided by 48-72 hours. Even at
their peak intensities the side effects were generally
mild to moderate. These were easily managed with
simple medication such as paracetamol and throat
lozenges for relief. Postural hypotension was
observed only in four subjects, each treated with a
different drug dosage: it manifested as tachycar-
dia beginning at 24 hours and persisted only for 8
hours except in one patient with high microfilare-
mia (20 µg/kg dosage) who remained intermit-
tently posturally hypotensive until the 4th day.
The serum chemistries and electrocardiograms
were within the range of normal values. A transient
rise in serum alkaline phosphatase level was ob-
served in four cases on the 2nd day but this returned
to normal values on the 7th day. Passage of round
worms was reported by three patients following
treatment.
The total average symptom scores. peak scores
and percentage of. patients showing symptoms
were analysed (Tables 1, 2).
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Fig 1–Kinetics of microfilaria clearance and recurre-
nce in all dose groups of ivermectin treatment
(n = 60).
To determine whether the side effects of the
treatment were drug dose related or merely a
function of the microfilaria parasite burden, the
mean reaction scores were compared among patient
groups. It was observed that the group treated
with 100 µg/kg of ivermectin had the lowest
mean reaction score, which was significantly dif-
ferent from that of the 50 µg (p<0.025) and
200 µg (p < 0.05) group (Fig 2). Total mean reac-
tion scores were further compared between two
groups with low and high microfilaremia. The
reaction scores obtained in the two low dose groups
w re independent of their microfilaria status.
However, in the rest (100 and 200 µg/kg) the
mean reaction scores were significantly higher
(p<0.05) in high microfilaremics (Fig 3).
DISCUSSION
Various clinical trials with ivermectin in the
treatment of onchocerciasis have proven its efficacy
as a potent microfilaricide with relatively few side
reactions and subsequently its usefulness in control
programs (Greene et al, 1985; WHO, 1989).
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DOSE GROUPS (µg/kg) DOSE GROUPS (µg/kg)
Fig 2–Post treatment mean r ction scores for iver-
mectin study groups (n = 60).
Fig 3–Post treatment mean reaction scores for predrug
high and low mf counts in four ivermectin dose
groups.
Table 1                
Adverse reactions seen in Wuchereria patients treated with various single oral doses of ivermectin.
Sign/Symptom
20 µg/kg
n=15
% of population with symptoms
50 µg/kg 100 µg/kg 200 µg/kg
n=l5 n=15 n=l5
Total
n=60
Fever
Anorexia
Nausea
Cough
Giddiness
Diaphoresis
Chill
Headache
Lethargy
Weakness
Myalgia
Arthralgia
Vomitting
Sore throat
Abd pain
93 100 100 100 98
80 100 53 67 75
20 60 20 27 32
33 80 53 73 60
67 87 60 67 70
  60 53 47 47 52
73 100 73 87 83
93 100 86.7 93 93
87 100 73 87 87
93 100 80 93 92
47 93 73 67 70
33       67 47 60 52
7 33 0 20 15
33 47 40 60 45
20 33 20 47 30
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Table 2
Comparison of reaction scores seen in Wuchereria bancrofti patients with high or low mf counts (n = 60).
Symptoms
Average total
score
LM HM
Peak score
LM HM
% of patients
with symptoms
LM HM
Fever 6.8 11.7 1.5 2.1 95.8 100.8
Diaphoresis 1.0 1.4 0.4 0.6 45.8 55.5
Chill 1.7 4.8 0.7 1.3 66.7 94.4
Headache 4.7 7.5 1.0 1.6 87.5 97.2
Lethargy 2.8 0.8 1.0 1.2 75.0 94.4
Weakness 3.6 8.0 0.9 1.2 83.3 97.2
Myalgia 3.5 4.5 0.7 1.0 58.3 77.3
Arthralgia 1.2   1.7 0.4 0.6 37.5 61.1
Anorexia 2.4 6.7 0.8 1.1 58.3 86.1
Nausea 0.4 1.7 0.2 0.4 16.7 41.7
Vomitting 0.1 0.4 0.1 0.2 8.3 19.4
Giddiness 2.2 5.3 0.7 1.2 50.0 83.3
Sore throat 1.6 2.3 0.4 0.6 37.5 50.0
C o u g h   2.5 4.1 0.5 0.9 41.7 72.2
Abd pain 0.9 1.1 0.3 0.4 20.8 36.1
LM = mf count < 1000/ml of blood (n =24)
HM = mf count > 1000/ml of blood (n=36)
The developments gave hope for similar applica-
tion of ivermectin in lymphatic filarial infections
as well. However, there is currently only limited
experience on the effectiveness of this drug in
various dose ranges from a few endemic areas
(Diallo et al. 1987; Kumaraswami et al, 1988;
Roux et al, 1989) and it remains a possibility that
regional differences may show variations either in
the response of infected patients to ivermectin the-
rapy or in the susceptibility of the parasites, that
will have important implications for the control
program if the drug can eventually be used. Un-
derstandably, there is a need to have wider experi-
ence of its effects in various population groups be-
fore an optimal dose of the drug can be recom-
mended for control programs. The present study
therefore evaluated four doses of ivermectin to
assess their relative efficacy and side reaction in
patients with moderate to very high levels of W.
bancrofti microfilaria in Orissa, India
All four drug dosage groups showed similar
microfilarial clearance patterns (Fig 1). but the
group receiving the highest dose (200 µg/kg)
showed the most rapid clearance, maintained the
lowest level of microfilaremia for the longest
period of time and with the lowest microfilarial
recurrence levels (20.9%) 6th months post-treat-
ment. Clearance of microfilariae from the blood
was complete in 37% (n=46) of subjects within  
two weeks. Nearly 98% of circulating microfilariae
was cleared within twelve hours of drug adminis-
tration. But the fall in the mf levels was not per-
manent and the counts started to rise gradually
from the 30th day onwards. Possibly. these ‘recur-
ring’ microfilariae were derived from those adult
worm(s) that were not affected/killed by a single
dose of ivermectin (Roux et al. 1989). Trials in
Tahiti (Roux et al. 1989) and Senegal (Diallo et al.
1987) indicated that a dose of 100 µg or more of
ivermectin per kg was more effective than that of
50 µg as microfilaricide and was not accompa-
nied by frequent side effects. However, studies in
South India have shown that doses of ivermectin
at 20-25 µg/kg were just as effective as those at
200 µg/kg in reducing the degree of microfilare-
mia and importantly, were associated with either
si nificantly fewer side effects or a tendency
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towards fewer side reactions than that with higher
doses.
In the present study, it was clear that the highest
dose (200 µg/kg) was most effective in clearing
microfilaremia but it was difficult to assess the
relationship of the dose with the side reactions as
the mf level in the four dose groups were not com-
parable. The total average score of symptoms like
anorexia, cough, giddiness, vomiting and abdomi-
nal pain was high in the 50 and 200 µg/kg dose
groups (Table 1). It may be noted that more of
high microfilaremics were included in the above
two groups. The average total reaction score of
patients receiving 20 and 100 µg were less than
those receiving 50 and 200 µg/kg doses (Fig 2).
This shows that the average reaction score is
independent of drug dose. The total average reac-
tion scores were found to be significantly higher
(p < 0.001) in the groups with high blood mf levels
(> 1000 mf/ml) (Table 2). Symptoms like vomiting,
sustained cough, severe anorexia and giddiness
were found mostly in the high microfilaria groups.
This indicates that the side reactions following
drug administration were rather the manifestation
of host inflammatory response to dying microfila-
riae (Piessens and Beldekas, 1979; Ottesen 1987;
Campbell, 1989). This was consistent with the
present observation that within 12 to 24 hours of
drug administration 97% of patients started com-
plaining discomfort when the maximum mf death
occurred. These reactions reached maximum
intensity between 24 to 48 hours of therapy and
subsided by 48 to 72 hours. All these side reactions
disappeared with the clearance of microfilaria.
In the present observation four patients with
high pretreatment mf count developed postural
hypotension. Postural hypotension has been seen
with DEC treatment both in onchocerciasis (Bry-
ceson et al. 1977; Awadzi et al, 1982) and lympha-
tic filariasis (Kumaraswami et al. 1988). Thus the
observed phenomenon was not related to direct
effect of drug although there is evidence in cats
that gamma-aminobutyric acid antagonists (as
ivermectin has been shown to be) (Campbell et al.
1983) can be hypotensive (Metheson et al, 1986).
Though mf clearance was observed equally in all
the groups, in the 200 µg/kg dose group there
was better mf clearance, delayed reappearance
and side reactions were within tolerable limits. To
determine the exact relationship of dose with
BANCROFTIAN MICROFILAREMIA
associated side reactions, patients with compara-
ble mf counts may be studied with different doses.
Besides, further studies are needed to evaluate the
effect of multiple doses or single doses of ivermec-
tin in preventing reappearance of microfilaria or
eradicating adult parasite from host.
Study results (efficacy) contrast markedly from
those reported from Madras and Haiti but similar
to Polynesia. Perhaps differences relate to inten-
sity of infections in these patients–something
we can not measure except very indirectly from mf
levels and inferentially from the prevalence levels
in various regions. It may be, as has been found in
onchocerciasis that initial treatment at more fre-
quent intervals (1-3 months) would be necessary
to achieve maximal benefit in mf reduction in
individuals with high infection living in regions of
high transmission whereas less frequent drug
administration would be sufficient in areas of
relatively low infection prevalence.
In our case, results here are the “poorest” in
terms of effectiveness of the single dose of iver-
mectin in reducing microfilaremia. These observa-
tions are extremely important and must be ex-
plained or at least taken into consideration, before
optimal ivermectin based control strategies are
formulated.
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